lobbying_activities: 1300531

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1300531	0b0fe808-c8ff-47a5-947f-f783fc250a53	Q3	MEHLMAN CONSULTING, INC.	284950	NATIONAL VENTURE CAPITAL ASSOCIATION	2012	third_quarter	MED	FDA reform: Changes to PDUFA (Prescription Drug User Fee Act) and MDUFA (Medical Device User Fee Act) programs. H.R. 4132, Faster Access to Specialized Treatments (FAST) Act; S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act; H.R. 2182, Generating Antibiotic Incentives Now (GAIN) Act of 2011; S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012 (See continuation page) H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. (Became Public Law 112-144)	Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of	60000		0	0	2012-10-16T13:02:38.363000-04:00